Back to top
more

Incyte (INCY)

(Real Time Quote from BATS)

$53.16 USD

53.16
1,212,157

+1.48 (2.86%)

Updated Apr 29, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Incyte (INCY) Reports Positive Long-Term Data From HS Study

Incyte's (INCY) povorcitinib shows sustained and durable efficacy across all treatment arms in the open-label extension period of the phase II HS study.

Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura

Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.

Incyte (INCY) Tops Q4 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of 5.08% and 4.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stocks' Q4 Earnings Due on Feb 7: VRTX, INCY and EXEL

Let us take a look at what is in store for some of the biotech stocks VRTX, INCY and EXEL, which are scheduled to report on Feb 7.

3 Reasons Why Growth Investors Shouldn't Overlook Incyte (INCY)

Incyte (INCY) could produce exceptional returns because of its solid growth attributes.

Incyte (INCY) to Report Q4 Earnings: What's in the Cards?

Incyte's (INCY) fourth-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Incyte (INCY) is a Great Momentum Stock: Should You Buy?

Does Incyte (INCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the past year and the momentum is anticipated to continue in 2023 as well.

LGND vs. INCY: Which Stock Should Value Investors Buy Now?

LGND vs. INCY: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights Verizon Communications, Honeywell International, CVS Health, Intuit and Incyte

Verizon Communications, Honeywell International, CVS Health, Intuit and Incyte are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Verizon, Honeywell & CVS Health

Today's Research Daily features new research reports on 16 major stocks,including Verizon Communications Inc. (VZ), Honeywell International Inc. (HON) and CVS Health Corporation (CVS).

Ligand (LGND) Down 3% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag

The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.

Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Incyte (INCY) Outperforms YTD: Will the Momentum Continue?

Incyte (INCY) outperforms the biotech industry in the year so far and the momentum should continue in 2023 as well.

Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates

Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.

Incyte (INCY) Q3 Earnings and Revenues Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Zacks.com featured highlights include e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell

e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell are part of the Zacks Screen of the Week article.

Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings

The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings are part of the Zacks top Analyst Blog.

Tirthankar Chakraborty headshot

4 Top-Rated Stocks to Buy Now for Solid Earnings Growth

Invest in stocks like e.l.f. Beauty (ELF), Monarch Casino & Resort (MCRI), Incyte (INCY) and Hubbell (HUBB) at the moment for superb earnings growth.

Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nalak Das headshot

A Bear Market Rally or Markets Forming a Solid Base: 5 Picks

We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.